Global clinical trial of HAE gene-editing therapy now fully enrolled
Patient enrollment has been completed in a global Phase 3 clinical trial that’s evaluating lonvoguran ziclumeran, also known as lonvo-z (NTLA-2002), a gene-editing therapy Intellia Therapeutics is developing to prevent swelling attacks in people with hereditary angioedema (HAE). Dubbed HAELO (NCT06634420), the trial — which…